Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter studyMaël Heiblig, Pierre Sujobert, Marcela A. Ferrada et al.|Blood|2022Cited by 212
Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective StudyMaël Heiblig, Pierre Sujobert, Marcela A. Ferrada et al.|Blood|2021Cited by 12
Focal facial myositis—a paraneoplastic syndrome?Tiago Beirão, P. Pinto, Joana Aleixo et al.|Lara D. Veeken|2023Cited by 0